Successful Treatment, with Chemotherapy and Intravenous Administration of Ascorbic Acid, of a Patient with Peripheral T-Cell Lymphoma, Not Otherwise Specified

Chiaki Tokoro; Atsushi Tashiro; Kenji Ina; Yoshiteru Tanaka; Hiroyuki Kobayakawa; Takashi Yoshida; Satoshi Kayukawa

doi:10.30683/1929-2279.2024.13.01

Authors

Chiaki Tokoro Palliative Care Team, Shinseikai Daiichi Hospital, Nagoya, Japan https://orcid.org/0009-0007-3277-1968
Atsushi Tashiro Palliative Care Team, Shinseikai Daiichi Hospital, Nagoya, Japan
Kenji Ina Palliative Care Team, Shinseikai Daiichi Hospital, Nagoya, Japan and Department of Geriatric Medicine, Shinseikai Daiichi Hospital, Nagoya, Japan https://orcid.org/0000-0001-8646-0611
Yoshiteru Tanaka Department of Pharmacy, Shinseikai Daiichi Hospital, Nagoya, Japan
Hiroyuki Kobayakawa Kobayakawa Clinic, Nagoya, Japan
Takashi Yoshida Department of Clinical Oncology, Nagoya Memorial Hospital, Nagoya, Japan https://orcid.org/0000-0002-1516-9613
Satoshi Kayukawa Department of Clinical Oncology, Nagoya Memorial Hospital, Nagoya, Japan https://orcid.org/0000-0002-9646-5114

DOI:

https://doi.org/10.30683/1929-2279.2024.13.01

Keywords:

Ascorbic acid, Peripheral T-cell lymphoma, Chemotherapy, Quality of life, EORTC QLQ-C30, Instrumental activities of daily living

Abstract

Here, we report the case of a 64-year-old man with peripheral T-cell lymphoma, not otherwise specified, who complained of diffuse lymphadenopathy and pancytopenia. This patient received the CHOP regimen followed by the CHP plus brentuximab vedotin regimen, and eventually experienced severe adverse effects, such as leukocytopenia and thrombocytopenia. He was then intravenously administered high doses of ascorbic acid to enhance the effects of chemotherapy drugs and reduce the intensity of the side effects. Positron emission tomography-computed tomography revealed a complete response of the lesions to combination therapy. This case report demonstrated the feasibility, efficacy, and acceptable toxicity of high-dose ascorbic acid in patients undergoing chemotherapy.

References

International T-cell lymphoma project. International T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124-30. https://doi.org/10.1200/JCO.2008.16.4558 DOI: https://doi.org/10.1200/JCO.2008.16.4558

Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood 2011; 117: 6756-67. https://doi.org/10.1182/blood-2010-05-231548 DOI: https://doi.org/10.1182/blood-2010-05-231548

Broccoli A, Zinzani PL. Peripheral T-cell lymphoma, not otherwise specified. Blood 2017; 129: 1103-12. https://doi.org/10.1182/blood-2016-08-692566 DOI: https://doi.org/10.1182/blood-2016-08-692566

AbouYabis AN, Shenoy PJ, Sinha R, et al. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol 2011; 2011: 623924. https://doi.org/10.5402/2011/623924 DOI: https://doi.org/10.5402/2011/623924

Horwitz S, O’Connor OA, Pro B, et al. The ECHELON-2 trial: 5-year results of a randomaized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol 2022; 33: 288-98. https://doi.org/10.1016/j.annonc.2021.12.002 DOI: https://doi.org/10.1016/j.annonc.2021.12.002

Cho H, Yoon DH, Shin D-Y, et al. Current treatment patterns and the role of upfront autologous stem cell transplantation in patients with peripheral T-cell lymphoma: A Korean nationwide, multicenter prospective registry study (CISL 1404). Cancer Res Treat 2023; 55: 684-92. https://doi.org/10.4143/crt.2022.1434 DOI: https://doi.org/10.4143/crt.2022.1434

Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1976; 73: 3685-9. https://doi.org/10.1073/pnas.73.10.3685 DOI: https://doi.org/10.1073/pnas.73.10.3685

Ngo B, Van Riper JM, Cantley LC, et al. Targeting cancer vulnerabilities with high-dose Vitamin C. Nat Rev Cancer 2019; 19: 271-82. https://doi.org/10.1038/s41568-019-0135-7 DOI: https://doi.org/10.1038/s41568-019-0135-7

Ma Y, Chapman J, Levine M, et al. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 2014; 6: 222ra18. https://doi.org/10.1126/scitranslmed.3007154 DOI: https://doi.org/10.1126/scitranslmed.3007154

Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 2004; 140: 533-7. https://doi.org/10.7326/0003-4819-140-7-200404060-00010 DOI: https://doi.org/10.7326/0003-4819-140-7-200404060-00010

Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76. https://doi.org/10.1093/jnci/85.5.365 DOI: https://doi.org/10.1093/jnci/85.5.365

Westin JR, Locke FL, Dickinson M, et al. Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed/ refractory large B-cell lymphoma. Clin Cancer Res 2023; 29: 1894-905. https://doi.org/10.1158/1078-0432.CCR-22-3136 DOI: https://doi.org/10.1158/1078-0432.CCR-22-3136

Akasaka H, Yonezawa H, Takahashi J, et al. Time-sparing screening method for mild cognitive impairment and early Alzheimerʼs disease: Self- and family reports using the TMIG index of competence. Nihon Ronen Igakkai zasshi 2020; 57: 182-94 [in Japanese]. https://doi.org/10.3143/geriatrics.57.182 DOI: https://doi.org/10.3143/geriatrics.57.182

Conradsson M, Rosendahl E, Littbrand H, et al. Usefulness of the Geriatric Depression Scale 15-item version among very old people with and without cognitive impairment. Aging Ment Health 2013; 17: 638-45. https://doi.org/10.1080/13607863.2012.758231 DOI: https://doi.org/10.1080/13607863.2012.758231

Watanabe M, Imagawa T. Factor structure of the short form of the geriatric depression scale (GDS): reliability, validity and cutoff points. Jpn J Personal 2013; 22: 193-7 [in Japanese]. https://doi.org/10.2132/personality.22.193 DOI: https://doi.org/10.2132/personality.22.193

Levine M, Rumsey SC, Daruwala R, et al. Criteria and recommendations for vitamin C intake. JAMA 1999; 281: 1415-23. https://doi.org/10.1001/jama.281.15.1415 DOI: https://doi.org/10.1001/jama.281.15.1415

Riordan HD, Casciari JJ, González MJ, et al. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J 2005; 24: 269-76.

Chen Q, Espey MG, Sun AY, et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008; 105: 11105-9. https://doi.org/10.1073/pnas.0804226105 DOI: https://doi.org/10.1073/pnas.0804226105

Kawada H, Sawanobori M, Tsuma-Kaneko M, et al. Phase I clinical trial of intravenous L-ascorbic acid following salvage chemotherapy for relapsed B-cell non-Hodgkin’s lymphoma. Tokai J Exp Clin Med 2014; 39: 111-5.